Financial Daily from THE HINDU group of publications
Tuesday, Jun 08, 2004
Financial Daily from THE HINDU group of publications Tuesday, Jun 08, 2004 |
||
|
|
||
|
Corporate
-
Alliances & Joint Ventures Marketing - Channels and Franchises NPIL inks deal with French firm for skincare products Our Bureau
Dr Swati Piramal, Director, Strategic Alliance, Nicholas Piramal India Ltd, with Dr Guy Macy, General Manager, Ducray & Aderma Dermatological Laboratories, Pierre Fabre, at a press conference in Mumbai on Monday. — Shashi Ashiwal
Mumbai , June 7 THE emerging `dermoceuticals' segment is increasingly finding favour in the domestic market, with another Indian pharma company tying up with a French company to promote skin-care products in India. Nicholas Piramal India Ltd (NPIL) announced its alliance with Laboratories Pierre Fabre of France to exclusively sell the latter's dermatology-related or skincare products in India. About a couple of months ago, Elder Pharma had inked a tie-up with Paris-based Laboratories Biorga, also to market French skin-care products in India. The domestic ethical (where products are sold on prescription) dermatology market is estimated at Rs 1,000 crore and growing at 4 per cent. NPIL will initially make and sell two products from Pierre Fabre's Ducray & Aderma range of personal products in India. Exomega, a moisturising cream and Kertyol-S, an anti-inflamatory and anti-fungal shampoo will be the first two products to be launched in India. Mr Vijay Shah, NPIL's Chief Operating Officer, told media persons that the products would be imported at the intermediate stage and the final form would be made locally. This would help bring the price of the products down, he said. Exomega is priced at Rs 100 for a 50 gram tube, while Kertyol would cost Rs 140 for 60 ml, said company officials. Both products are ethical and would be sold on a prescription and promoted through dermatologists and general physicians, they said. While NPIL looks at making Rs three to five crore from these products in it's first year of operation, the company expects to earn about Rs 20 crore from this in-licensing agreement in another couple of years. The agreement is for a period of five years and NPIL top brass said that they would look at expanding the scope of the deal to more products and markets. Meanwhile, NPIL would also look at post-marketing surveillance of the two products in India.
More Stories on : Alliances & Joint Ventures | Channels and Franchises | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|